Zacks Investment Research Upgrades ELEKTA AB/ADR (EKTAY) to Hold
According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “
Separately, ValuEngine cut ELEKTA AB/ADR from a “buy” rating to a “hold” rating in a report on Tuesday, April 9th.
ELEKTA AB/ADR (OTCMKTS:EKTAY) last posted its quarterly earnings results on Friday, February 22nd. The company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $367.04 million for the quarter. ELEKTA AB/ADR had a return on equity of 16.86% and a net margin of 9.35%. As a group, analysts anticipate that ELEKTA AB/ADR will post 0.35 EPS for the current year.
About ELEKTA AB/ADR
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
Read More: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.